Cameron Chalker

Cameron Chalker

Auto-generated profile, based on publicly available information

Cameron Chalker

Division of Hematology and Medical Oncology Oregon Health & Science University (OHSU), Knight Cancer Institute Portland Oregon USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
CCCameron Chalker
Cameron Chalker
JVJenna M. Voutsinas
Jenna M. Voutsinas
QWQian Vicky Wu
Qian Vicky Wu
RSRafael Santana‐Davila
Rafael Santana‐Davila
VHVictoria Hwang
Victoria Hwang
CRCristina P. Rodriguez
Cristina P. Rodriguez
Background: Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this population is therefore unknown.Methods: We retrospectively reviewed RMHNSCC patients who received 1+ dose of ICI at our institution between 2013 and 2019. Demographic and clinical data were obtained; the latter included objective response (ORR), toxicity, and any unplanned hospitalization (UH). Associations were explored using uni‐ and multivariate analysis. Overall survival (OS) was estimated using a Cox proportional hazards model; ORR, toxicity, and UH were evaluated with logistic regression.Results: Of the 152 patients, 29 (19%) had an ECOG PS ≥2. Sixty‐six (44%) experienced toxicity; 54 (36%) had a UH. A multivariate model for OS containing PS, smoking status, and HPV status demonstrated a strong association between ECOG ≥2 and shorter OS (p < 0.001; HR = 3.30, CI = 2.01–5.41). An association between OS and former (vs. never) smoking was also seen (p < 0.001; HR = 2.17, CI = 1.41–3.35); current smoking did not reach statistical significance. On univariate analysis, poor PS was associated with inferior ORR (p = 0.03; OR = 0.25, CI = 0.06–0.77) and increased UH (p = 0.04; OR = 2.43, CI = 1.05—5.71). There was no significant association between toxicity and any patient characteristic.Conclusions: We observed inferior OS, ORR, and rates of UH among ICI‐treated RMHNSCC patients with ECOG 2/3. Our findings help frame discussion of therapeutic options in this poor‐risk population.

4 April 2019 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
CCCameron Chalker
Cameron Chalker
HOHannah O'NEill
Hannah O'NEill
FCFaith Cranfield
Faith Cranfield
Objectives To summarise the current body of published evidence on the use of low-dose and/or adjuvant methadone in the palliative care setting. Methods The authors searched multiple databases (PubMED, SCORPUS, EMBASE and the Cochrane library) for relevant articles using the terms ‘methadone’, ‘palliative’, ‘low dose’ and ‘adjuvant’. The review was restricted to articles published between 2003 and 2018. Paediatric and single-case studies were also excluded. Evidence quality was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) method. Results Our search yielded 171 results, of which seven met the inclusion criteria. Four were retrospective chart reviews, one was a retrospective cohort study, one was a case series and one was a double-blind randomised control trial. The overall quality was found to be very low. Of the seven articles, all seven reported some improvement in pain with the addition of low-dose or adjuvant methadone. This improvement was statistically significant in four out of seven articles; statistical significance was not commented on in the remaining three articles. Conclusion While case series and chart reviews offer promising results about the utility of adjuvant and/or low-dose methadone in the management of complex pain, the very low evidence quality, relative dearth of studies and near absence of randomised controlled trials make it impossible to draw firm conclusions. Thus, while very preliminary evidence suggests methadone is a potentially effective and valuable agent, further research must be performed before such findings can be implemented into clinical practice.

15 June 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
CCCameron Chalker
Cameron Chalker
BYBurçak Yilmaz
Burçak Yilmaz
KTKristin Trone
Kristin Trone
GPGenevieve Parecki
Genevieve Parecki
ACAthena Chen
Athena Chen
ASAlexandra O. Sokolova
Alexandra O. Sokolova
Prostate cancer (PCa) seldom metastasizes to the thyroid gland, and only a limited number of cases are documented in the literature. The application of a relatively recent and highly sensitive imaging technique, prostate-specific membrane antigen (PSMA) positron emission tomography—computed tomography (PET/CT), has enhanced the identification of metastatic disease. Nevertheless, as PSMA is expressed in various tissue types, the clinical importance of a PSMA-avid thyroid lesion remains largely uncertain. A minor, yet noteworthy, percentage of these lesions are ultimately determined to be malignant. Here we describe the case of a 70-year-old man with a past medical history of Lynch syndrome who presented to an outpatient oncologic clinic for management of very high risk localized PCa. He developed metastatic recurrence and his disease progressed through several lines of therapy, including immunotherapy and targeted treatments. He was found to have a new, intense PSMA uptake in an existing, previously benign thyroid nodule. Sonographic evaluation revealed changing morphology despite grossly stable size. Repeat biopsy confirmed the unusual finding of PCa metastasis to a known thyroid nodule. The shift in PSMA avidity played a pivotal role in discerning this metastatic deposit. There is a potential risk that such lesions may be inadequately acknowledged. The impact of the patient’s Lynch syndrome on this presentation remains uncertain.

8 May 2024 in Current Problems in Cancer
Verified
Journal Article
Closed access
CCCameron Chalker
Cameron Chalker
BCBrie Chun
Brie Chun
ASAlexandra O. Sokolova
Alexandra O. Sokolova

30 April 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
CBColin P. Bergstrom
Colin P. Bergstrom
CCCameron Chalker
Cameron Chalker
JAJoseph Allen
Joseph Allen
HSHong Song
Hong Song
BYBurcak Yilmaz
Burcak Yilmaz
AKAli Raza Khaki
Ali Raza Khaki
Radioligand therapy with lutetium-177-labeled prostate-specific membrane antigen 177Lu-PSMA-617 has demonstrated survival benefits in metastatic castration-resistant prostate cancer (mCRPC), yet prognostic markers in real-world settings remain poorly defined. Baseline hematologic parameters may influence both treatment safety and outcomes, but their prognostic role is uncertain. We conducted a multi-institutional, retrospective cohort study of 180 patients with mCRPC treated with ≥ 1 cycle of 177Lu-PSMA-617 between March 2019 and September 2024 at Stanford University and Oregon Health and Science University. Clinical data, baseline laboratory values, and treatment outcomes were abstracted. Associations between hematologic parameters: absolute neutrophil count (ANC), hemoglobin, neutrophil-lymphocyte ratio (NLR), and platelet count with outcomes were assessed. Prostate-specific antigen (PSA) responses were compared with chi-squared testing. Overall survival (OS) was estimated and compared using Kaplan-Meier. Multivariable Cox regression adjusted for age, race, prior therapies, and taxane exposure. Median age at treatment initiation was 65 years (interquartile range [IQR] 59-70), and median prior lines of therapy was 5 (IQR 3-6). PSA50 and PSA90 responses occurred in 51% and 24% of patients, respectively, without a significant association to baseline ANC, hemoglobin, or platelet counts. Median OS for the cohort was 13 months. On univariable analysis, hemoglobin < 10 g/dL was associated with shorter OS (median 8 vs. 15 months; hazard ratio [HR] 1.85, 95% CI, 1.17-2.91; P = .008), as was an ANC > 6500/µL (upper limit of normal) (median 11 vs. 14 months; HR 1.58, 95% CI, 1.04-2.38; P = .031). Platelet count and NLR were not associated with OS. In multivariable analysis, both hemoglobin < 10 g/dL and ANC > 6500/µL remained independently associated with increased shorter OS. In this real-world multicenter cohort, baseline hemoglobin < 10 g/dL and ANC > 6500/µL were associated with shorter OS in patients with mCRPC treated with 177Lu-PSMA-617. Prospective validation integrating hematologic, imaging, and molecular biomarkers is warranted.

23 October 2026 in Head & Neck
Verified
Journal Article
Closed access
CCCameron Chalker
Cameron Chalker
JBJason C. Burton
Jason C. Burton
AKAndy Kaempf
Andy Kaempf
JLJeong Youn Lim
Jeong Youn Lim
SLSarah Lowry
Sarah Lowry
EREric J. Roeland
Eric J. Roeland